CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 120 countries and employs 28,500+ people.
Frequently Asked Questions (FAQs)
Pictured: CSL Head Office Building in Melbourne, Australia
Find answers to frequently asked questions about CSL’s business units, therapeutic focus areas and commitment to innovation.
CSL's three key areas of expertise are Rare and Serious Diseases, Vaccines, Iron Deficiency and Nephrology.
Learn more about CSL's areas of expertise
CSL's core values are Patient Focus, Innovation, Integrity, Collaboration and Superior Performance. These values guide the company's actions and decisions.
Learn more about CSL’s Values
CSL has 5 core Therapeutic Areas, these are:
- Immunoglobulins
- Hematology
- Cardiovascular and Renal
- Immunology
- Vaccines
CSL Behring is a business unit of CSL.
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients' needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
CSL Seqirus is a business unit of CSL.
As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries.
CSL Vifor is a business unit of CSL.
With our iron deficiency and iron deficiency anemia expertise in heart failure, kidney disease, gastroenterology or inflammatory bowel disease, patient blood management and women’s health, CSL Vifor helps patients affected by these conditions to live better, healthier lives.
CSL Plasma is a subsidiary of CSL, a global biotechnology company.
CSL Plasma operates one of the world’s largest and most sophisticated plasma donation networks, with nearly 330 donation centers in the U.S. and Europe. Plasma collected at CSL Plasma facilities is used by CSL for the sole purpose of manufacturing lifesaving plasma-derived therapies for people in more than 100 countries.
Brian McNamee is CSL's Chair.
Gordon Naylor is CSL's Chief Executive Officer (CEO) and Managing Director.
Ken Lim is CSL's Chief Financial Officer (CFO).
To learn more about CSL's Leadership Team and Board, please visit the Our Leadership page on CSL.com
CSL is dedicated to sustainability and has set goals to minimize its environmental impact. The company is actively working to reduce its carbon footprint and improve its overall environmental performance.
Learn more about CSL’s commitment in our Sustainability section of CSL.com
Yes we have an Impact Report.
CSL's Impact Report highlights our work in financial year 2025 (FY2025) to create lifesaving medicines, safeguard public health, advance science and contribute positively to the communities where we live and work